A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

PathPresenter Empowers Biorepositories to Share Pathology Imaging Data for Biomedical Research

New enterprise workflow platform creates a secure and compliant ecosystem for sharing data and providing analytical tools to maximize use

PathPresenter, the global image sharing platform for pathology, announced today a new enterprise workflow platform that empowers biorepositories and databanks to share imaging data with other institutions, AI companies, pharma, and industry for biomedical research. The scalable and secure cloud-based platform makes the imaging data easily available to researchers and provides smart tools to maximize collaborative research for the ultimate benefit of patients and donors. By adopting the PathPresenter platform, biorepositories and organizations have a unique opportunity to generate a return on investment for their digital pathology infrastructure.

Watch a video overview of the new research platform by PathPresenter founder, Dr. Rajendra Singh, here.

Biorepositories play a crucial role in the collection, storage, and delivery of high-quality biospecimens to researchers, while providing honest brokerage services for de-identification of these biospecimens. This facilitates the sharing of knowledge among institutions and promotes meaningful translational biomedical research. The emergence of digital pathology has opened new possibilities for leveraging biorepositories by enabling the sharing of imaging data for research purposes. With the growing use of digital slides in research, these data banks play a vital role in data distribution. However, there has been a lack of well-established, standardized workflows that facilitate the easy distribution of data, collaboration among researchers, and user-friendly tools for working with whole slide images in research.

PathPresenter’s scalable and secure cloud-based digital workflow platform empowers biorepositories to establish next generation repositories of whole slide images. Managed by the organization, PathPresenter allows biorepositories to upload whole slide images along with de-identified tissue metadata such as diagnosis, tumor grade, treatment information, and outcome data. It then provides administrative tools that enable researchers from anywhere in the world to register for access. Once vetted and approved by the organization, research users can search and utilize the data stored in the repository. The platform provides powerful search capabilities that allow researchers to enter specific criteria to find relevant datasets for their research. The data can be downloaded or aggregated in private folders for online research, including the ability to define regions of interest, add annotations, incorporate metadata, and even deploy AI modules. PathPresenter offers features to manage user roles and permissions, such as viewing, editing, or deleting annotations, as well as tools to audit annotator progress. Researchers can build entire research projects on the PathPresenter platform, as well as test AI models without exhausting limited biospecimens.

An early adopter of the PathPresenter research platform was the Food and Drug Administration (FDA) which used it to centralize the collection of tumor infiltrating lymphocytes in breast adenocarcinoma for the validation of de-novo AI technologies. For more information see here: https://www.fda.gov/media/148912/download.

Recently, the Midwestern division of the Cooperative Human Tissue Network (CHTN) and PathPresenter have collaborated to establish an innovative tissue repository. The main goal of this collaborative project is to build an elastic compute cloud-based infrastructure and scalable workflows, ensuring easy accessibility of data to researchers. Additionally, the project aims to provide intelligent tools that enhance collaborative research, with the ultimate objective of utilizing the data to benefit patients and donors.

“The biobank of the future requires not only the collection and timely delivery of high quality biospecimens for researchers, but also simultaneous annotation and de-identification of these biospecimens that can be easily accessible to the research community,” said Dr. Anil Parwani, Principal Investigator for the Midwestern division of CHTN. “We chose PathPresenter as our workflow platform due to a combination of factors, including the tried and tested nature of the viewer, its cloud-based infrastructure to enable easy scaling, tools to centralize collection of annotations and sharing of images, embedded AI that can be released to members as needed, and the flexibility of the platform for customization to the needs of CHTN.”

“PathPresenter has always been focused on creating efficiencies and value for pathology departments/organizations and truly becoming the center of personalized care for our patients,” added Dr. Rajendra Singh, co-founder of PathPresenter. “Our ‘smart’ data distribution workflow is another step in the same direction that will allow biorepositories hosted by pathology departments to securely share data with multiple researchers and help enhance research.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
The addition of Olink to the Synexa Life Sciences technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more.

By using this website you agree to accept Medical Device News Magazine Privacy Policy